Veradermics, Incorporated
MANE
$123.70
+12.28%
Veradermics, Incorporated is a clinical-stage biopharmaceutical company focused on developing therapeutics for aesthetic and dermatological conditions. As a niche player in the biotechnology industry, it targets pervasive treatment challenges in prevalent skin disorders. The stock has recently attracted attention due to its dramatic price surge since its IPO in February 2026, driven by investor optimism around its pipeline and potential market opportunities. The narrative centers on whether the company can successfully advance its candidates through clinical trials and achieve commercialization.…
MANE
Veradermics, Incorporated
$123.70
Investment Opinion: Should I buy MANE Today?
Rating: Hold. The thesis is that Veradermics has strong liquidity and no debt, but its extreme valuation and lack of revenue make it too speculative for a buy recommendation. Analyst consensus is not available due to limited coverage, but the estimated EPS of $4.98 implies a forward PE of 26x if achieved, which is reasonable for a growth biotech.
Supporting evidence: The company has a current ratio of 16.66 and negligible debt, providing a cash runway. However, it has zero revenue, negative EPS of -$0.053, and a negative PCF ratio of -18.49, indicating cash burn. The stock has rallied 243% since IPO, far outpacing the S&P 500's 19.1% gain over the same period, but this also introduces overvaluation risk. The analyst revenue estimate of $528.9 million is aggressive and unproven.
Risks & Conditions: The biggest risks are pipeline failure and dilution. This Hold would upgrade to Buy if the company announces positive Phase II/III results or if the stock pulls back to the $80 level (near the 52-week low of $32 is too extreme). It would downgrade to Sell if the company announces a failed trial or if insider selling emerges. Overall, the stock is overvalued relative to its fundamentals but may be fairly valued if pipeline expectations are met.
Sign up to view all
MANE 12-Month Price Forecast
The AI assessment is bearish due to the extreme valuation disconnect and lack of revenue. While the company has a strong balance sheet, the stock's price already prices in significant pipeline success. The 243% rally since IPO increases downside risk, and the limited analyst coverage adds uncertainty. The base case of range-bound trading is most likely, but the bear case has a higher probability than the bull case given the binary nature of clinical-stage biotech. An upgrade to neutral would require positive trial data or a significant pullback in price.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veradermics, Incorporated's 12-month outlook, with a consensus price target around $160.81 and implied upside of +30.0% versus the current price.
Average Target
$160.81
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$99 - $161
Analyst target range
Only 2 analysts cover the stock, with a consensus estimated EPS of $4.98 and estimated revenue of $528.9 million for the next fiscal year. No buy/hold/sell distribution or average target price is provided. The implied upside or downside cannot be calculated without a target price. The low and high estimates for EPS and revenue are identical, suggesting limited coverage and potential lack of diversity in views. The wide gap between current negative EPS and estimated positive EPS implies aggressive growth expectations. Insufficient analyst coverage is available, which is common for a recently IPO'd small-cap biotech. This limited coverage can lead to higher volatility and less efficient price discovery.
Drowning in data?
Find the real signal!
Bulls vs Bears: MANE Investment Factors
Veradermics is a high-risk, high-reward clinical-stage biotech with no revenue but a strong balance sheet and a dramatic price surge since its IPO. The bull case hinges on successful pipeline development and the analyst-estimated revenue of $528.9 million, while the bear case centers on the lack of fundamental support and extreme valuation. Currently, the bear case has stronger evidence given the speculative nature and overbought technicals, but the bull case could prevail if clinical trials succeed. The single most important tension is whether the company can achieve the aggressive revenue estimates, which would validate the current market cap.
Bullish
- Massive Price Appreciation Since IPO: The stock has surged from its IPO price of $37.75 in February 2026 to $129.74, a gain of 243% in just five months. This reflects strong investor optimism about the company's pipeline and potential market opportunities in aesthetic and dermatological conditions.
- Strong Liquidity with Current Ratio of 16.66: The current ratio of 16.66 indicates that the company has ample short-term assets to cover its liabilities, reducing near-term bankruptcy risk. This is particularly important for a clinical-stage biotech that may not generate revenue for years.
- Negligible Debt with Debt-to-Equity Near Zero: The debt-to-equity ratio is -0.000033, effectively zero, meaning the company has no significant debt burden. This allows it to focus on R&D without the pressure of debt servicing, a key advantage for a pre-revenue biotech.
- Analyst Estimates Suggest Massive Revenue Growth: Analysts estimate revenue of $528.9 million and EPS of $4.98 for the next fiscal year, implying a dramatic turnaround from current negative earnings. If achieved, this would validate the pipeline and drive significant upside.
Bearish
- Zero Revenue and Negative Earnings: The company has no revenue and a negative EPS of -$0.053, typical for a clinical-stage biotech. With no sales, the stock's valuation is entirely speculative, relying on future pipeline success that may never materialize.
- Extreme Valuation with No Fundamental Support: Traditional valuation metrics like PE and PS are meaningless due to negative earnings and zero revenue. The stock trades at a market cap of $1.32 billion with no sales, implying a PS ratio of infinity, far above any industry average.
- Limited Analyst Coverage and High Uncertainty: Only 2 analysts cover the stock, and their estimates are identical, suggesting limited diversity of opinion and potential lack of depth in analysis. This can lead to higher volatility and less efficient price discovery.
- Potential Overbought Conditions After 243% Rally: The stock has rallied 243% from its IPO and is trading at 98.9% of its 52-week high. The rapid ascent suggests overbought conditions, increasing the risk of a sharp pullback if sentiment shifts or news disappoints.
MANE Technical Analysis
The stock is in a strong uptrend, with a 1-year price change of approximately 243% (from IPO at $37.75 to $129.74). The current price of $129.74 is near the 52-week high of $131.24, trading at 98.9% of the 52-week range, indicating bullish momentum and potential overextension. The stock has rallied from a 52-week low of $32.00, reflecting a massive gain of over 300% from the low. Short-term momentum is accelerating, with a 1-month price change of +32.1% and a 3-month change of +102.1%, far outpacing the S&P 500's 1-month decline of -1.25% and 3-month gain of 13.56%. The relative strength index (RSI) is not provided, but the rapid ascent suggests overbought conditions. The 52-week high of $131.24 acts as resistance; a breakout above this level could signal further upside, while a breakdown below the 52-week low of $32.00 would be catastrophic. Beta is not available, but the stock's volatility is evident from its 21.32% maximum drawdown and wide price swings.
Beta
—
—
Max Drawdown
-21.3%
Largest decline past year
52-Week Range
$32-$131
Price range past year
Annual Return
—
Cumulative gain past year
| Period | MANE Return | S&P 500 |
|---|---|---|
| 1m | +28.5% | +0.0% |
| 3m | +66.9% | +7.6% |
| 6m | — | +9.1% |
| 1y | — | +21.3% |
| ytd | — | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MANE Fundamental Analysis
Revenue data is not available as the company is pre-revenue, with zero reported revenue in the valuation data. The company is not yet generating sales, typical for a clinical-stage biotech. Net income is negative, with an EPS of -$0.053, reflecting ongoing R&D expenses. Gross margin is 0% due to no revenue. The company is unprofitable, but the negative EPS is small relative to the stock price, indicating early-stage losses. The balance sheet shows a current ratio of 16.66, indicating strong liquidity, and a debt-to-equity ratio of -0.000033, suggesting negligible debt. However, ROE is 57.8%, which is misleading due to negative equity (as indicated by a negative price-to-book ratio of -10.94). Free cash flow is not provided, but the negative PCF ratio of -18.49 implies negative cash flow. The company likely relies on equity financing to fund operations.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MANE Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is used, but PS is 0 due to zero revenue. Therefore, the trailing PE of -15.86 and forward PE of -42.71 are not meaningful. The EV/EBITDA of -18.61 also reflects negative EBITDA. Given the lack of positive earnings or revenue, traditional valuation metrics are not applicable. The stock is trading at a significant premium to the industry average, but no industry average is provided. The negative PEG ratio of -0.0099 suggests negative earnings growth expectations. Historical ratios are not available, but the stock's valuation is purely based on future potential, with no fundamental support. The market is pricing in optimistic expectations for pipeline success.
PE
-15.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-18.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The company has zero revenue and negative net income, with an EPS of -$0.053, indicating ongoing cash burn from R&D. While the current ratio of 16.66 provides liquidity, the negative free cash flow (PCF ratio of -18.49) means the company relies on equity financing, which could dilute shareholders. The negative equity (PB ratio of -10.94) is a red flag, though the negligible debt mitigates immediate solvency risk. The primary financial risk is that the company fails to achieve the analyst-estimated revenue of $528.9 million, leading to a valuation collapse.
Market & Competitive Risks: The stock trades at an extreme premium with no fundamental support, making it highly susceptible to sentiment shifts. The 243% rally since IPO suggests overbought conditions, and a 21.32% max drawdown already demonstrates volatility. As a small-cap biotech with only 2 analysts covering it, the stock is prone to large swings on news. Competitive risks include other biotechs targeting similar dermatological conditions, though no specific competitors are identified. Macro risks are less relevant given the company's early stage, but rising interest rates could reduce appetite for speculative stocks.
Worst-Case Scenario: If clinical trials fail or are delayed, the stock could crash to its 52-week low of $32.00, representing a 75% decline from the current price of $129.74. This scenario would likely occur if a key pipeline candidate fails in Phase II or III trials, eroding investor confidence and leading to analyst downgrades. Given the lack of revenue, the stock's value would revert to near cash value, which is uncertain but likely below $32.00.
FAQ
The key risks are: 1) Pipeline failure: if clinical trials fail, the stock could crash to $32.00 or below, a 75% loss. 2) Dilution: the company burns cash (PCF ratio -18.49) and may need to issue shares, diluting existing holders. 3) Valuation risk: the stock is priced for perfection, and any disappointment could lead to a sharp correction. 4) Limited coverage: only 2 analysts cover the stock, leading to higher volatility and less price discovery. The most severe risk is pipeline failure, which would destroy the investment thesis.
The 12-month forecast is highly uncertain. The bull case (20% probability) sees the stock reaching $150-$200 on positive trial results. The base case (50% probability) expects the stock to trade between $100 and $130 as the company progresses without major news. The bear case (30% probability) sees a decline to $32-$60 if trials fail. The most likely scenario is the base case, but the bear case has a higher probability than the bull case due to the binary nature of clinical-stage biotech. Investors should monitor trial catalysts closely.
MANE is extremely overvalued based on traditional metrics. With zero revenue and negative earnings, its price-to-sales ratio is infinite, and its trailing PE is -15.86. The stock trades at a market cap of $1.32 billion with no sales, implying a valuation that relies entirely on future expectations. Compared to the biotech industry, this is a significant premium. The only way the stock is not overvalued is if it achieves the analyst-estimated revenue of $528.9 million, which would give it a forward PS ratio of 2.5x, reasonable for a growth biotech. However, that outcome is highly uncertain.
MANE is a high-risk, high-reward speculative stock. With zero revenue and a market cap of $1.32 billion, the stock is priced for perfection. The potential upside is significant if pipeline candidates succeed, but the downside is equally large, with a 75% decline to the 52-week low of $32.00 possible. Given the extreme valuation and lack of fundamental support, it is only suitable for investors who can tolerate a total loss and have a long-term horizon. For most investors, it is not a good buy at current levels.
MANE is suitable for long-term investment only if the investor has a high risk tolerance and a horizon of 3-5 years to allow for pipeline development. Short-term trading is extremely risky due to the stock's high volatility (21.32% max drawdown) and overbought conditions. The stock has no dividend and negative earnings, so it is not an income investment. A minimum holding period of 3 years is recommended to give time for clinical trials to read out. However, even long-term investors should be prepared for a potential total loss.
